Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.69 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.69 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.69 |
| ▸ | CHRND | Q07001 | 9/20 | 0.67 |
| ▸ | CHRNA1 | P02708 | 5/20 | 0.67 |
| ▸ | CHRNG | P07510 | 5/20 | 0.67 |
| ▸ | CHRNB1 | P11230 | 5/20 | 0.67 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14598337 | 1.00 | CHRNB2 (0.69) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL5493873 | 0.88 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL5487472 | 0.88 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL31654046 | 0.88 | CHRNB2 (0.62) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL14765234 | 0.87 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL14761090 | 0.86 | CHRNB2 (0.63) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL14761539 | 0.86 | CHRNB2 (0.63) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL14761840 | 0.86 | CHRNB2 (0.63) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL14761872 | 0.86 | CHRNB2 (0.63) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL14761410 | 0.86 | CHRNB2 (0.63) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753782-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| WO-2005123770-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | CHRNB2 3208/4885CHRNB4 3005/4885CHRNA3 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.